Munich Reinsurance Co Stock Corp in Munich Invests $7.93 Million in Solventum Corporation $SOLV

Munich Reinsurance Co Stock Corp in Munich acquired a new stake in shares of Solventum Corporation (NYSE:SOLV) during the first quarter, Holdings Channel reports. The institutional investor acquired 121,422 shares of the company’s stock, valued at approximately $7,929,000.

Several other hedge funds have also recently made changes to their positions in the company. Nicholas Hoffman & Company LLC. lifted its position in Solventum by 113.3% during the 1st quarter. Nicholas Hoffman & Company LLC. now owns 17,294 shares of the company’s stock worth $1,129,000 after acquiring an additional 9,188 shares during the period. Canvas Wealth Advisors LLC increased its holdings in shares of Solventum by 11.9% in the first quarter. Canvas Wealth Advisors LLC now owns 8,242 shares of the company’s stock valued at $538,000 after purchasing an additional 877 shares during the period. Appleton Partners Inc. MA raised its stake in shares of Solventum by 60.2% in the first quarter. Appleton Partners Inc. MA now owns 141,689 shares of the company’s stock worth $9,252,000 after purchasing an additional 53,243 shares during the last quarter. V Square Quantitative Management LLC lifted its holdings in shares of Solventum by 14.3% during the first quarter. V Square Quantitative Management LLC now owns 5,977 shares of the company’s stock worth $390,000 after purchasing an additional 749 shares during the period. Finally, HB Wealth Management LLC lifted its holdings in shares of Solventum by 3.5% during the first quarter. HB Wealth Management LLC now owns 4,292 shares of the company’s stock worth $280,000 after purchasing an additional 147 shares during the period.

Solventum Stock Down 1.3%

Shares of SOLV opened at $75.29 on Thursday. The company has a market capitalization of $13.04 billion, a price-to-earnings ratio of 9.23, a PEG ratio of 1.18 and a beta of 0.66. Solventum Corporation has a 52 week low of $62.38 and a 52 week high of $88.20. The stock’s 50-day moving average price is $75.87 and its 200-day moving average price is $74.34. The company has a quick ratio of 0.75, a current ratio of 1.07 and a debt-to-equity ratio of 0.96.

Solventum (NYSE:SOLV) last announced its quarterly earnings results on Tuesday, May 5th. The company reported $1.48 earnings per share for the quarter, beating the consensus estimate of $1.35 by $0.13. Solventum had a return on equity of 23.51% and a net margin of 17.33%.The company had revenue of $2.01 billion during the quarter, compared to analysts’ expectations of $1.97 billion. During the same period last year, the business earned $1.34 earnings per share. Solventum’s quarterly revenue was down 3.0% on a year-over-year basis. Solventum has set its FY 2026 guidance at 6.600-6.600 EPS. On average, sell-side analysts predict that Solventum Corporation will post 6.58 EPS for the current year.

Analysts Set New Price Targets

Several equities analysts recently weighed in on the stock. KeyCorp increased their price target on shares of Solventum from $92.00 to $93.00 and gave the stock an “overweight” rating in a report on Wednesday, May 6th. BTIG Research restated a “buy” rating and set a $89.00 price objective on shares of Solventum in a research note on Wednesday, May 6th. UBS Group downgraded shares of Solventum from a “buy” rating to a “neutral” rating and set a $50.00 price objective on the stock. in a report on Thursday, May 14th. Stifel Nicolaus cut their price objective on shares of Solventum from $105.00 to $90.00 and set a “buy” rating on the stock in a research note on Wednesday, May 6th. Finally, Weiss Ratings cut shares of Solventum from a “hold (c+)” rating to a “hold (c)” rating in a report on Friday, June 26th. Seven research analysts have rated the stock with a Buy rating, six have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Solventum currently has an average rating of “Hold” and a consensus price target of $83.50.

Solventum Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes.